Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

ABSTRACT: Since the late 1990s, there has been a steady decline in cancer-related mortality, in part related to the introduction of so-called targeted therapies. Intended to interfere with a specific molecular pathway, these therapies have, paradoxically, led to a number of effects off their intended cancer tissue or molecular targets. The latest examples are tyrosine kinase inhibitors targeting the Philadelphia Chromosome mutation product, which have been associated with progressive atherosclerosis and acute vascular events. In addition, agents designed to interfere with the vascular growth factor signaling pathway have vascular side effects ranging from hypertension to arterial events and cardiomyocyte toxicity. Interestingly, the risk of cardiotoxicity with drugs such as trastuzumab is predicted

SUBMITTER: Herrmann J 

PROVIDER: S-EPMC4817363 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature